Can-Fite received notice that a patent is ready to be granted for Piclidenoson use in diseases including Lowe syndrome. This strengthens legal protection, though the ongoing Phase 2 study means patient benefits are not yet established.
The patent could strengthen Can-Fite's legal protection for Piclidenoson in rare diseases. Its value still depends on the ongoing Phase 2 study, so the benefit is promising but not yet proven in patients.
Follow Can-Fite BioPharma (CANF) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CANF